Search - tctmd.com

Displaying 1 - 20 of 48

Sort: Relevancy | Date

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

L.A. McKeown

November 01, 2024

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

Todd Neale

October 30, 2024

Presentation TCT 2024

AS in Women

Presenter: Renuka Jain

October 29, 2024

Presentation TCT 2024

Procedural Considerations

Presenter: Kendra Grubb

October 29, 2024

Presentation TCT 2024

Case Background and Valve Selection Discussion

Presenter: Bruce Rutkin

October 29, 2024

Presentation TCT 2024

Case Outcome

Presenter: Bruce Rutkin

October 29, 2024

Presentation TCT 2024

SMART Data

Presenter: Howard Herrmann

October 29, 2024

Presentation TCT 2024

The Evolution of Transcatheter Mitral Valve Repair: Technical and Procedural Insights from an Early Human Feasibility Program (Case-Based)

Presenter: Alexandre Abizaid

October 29, 2024

Presentation TCT 2024

TCT 165: Comparison of Paravalvular Leak in SAPIEN 3 and EVOLUT PRO Valves in Transcatheter Aortic Valve Replacement: A Multicenter Registry

Presenter: Anthony Matta

October 28, 2024

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

News Conference News TCT 2023

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

Caitlin E. Cox

November 03, 2023

News Conference News TCT 2023

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

Michael O'Riordan

November 01, 2023

News Conference News TCT 2023

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

L.A. McKeown

October 27, 2023

Presentation TCT 2023

Optimizing Outcomes With Self-Expanding Valves: The OPTIMIZE PRO Study and Evolut PRO Plus and FX Valves

Presenter: Steven Yakubov

October 25, 2023

Presentation TCT 2023

TCT 248: Assessment of Coronary Cannulation, Commissure and Coronary Alignment post TAVR with the New Supra-Annular, Self-Expanding Evolut FX System

Presenter: Guilherme Attizzani

October 25, 2023

Presentation TCT 2023

TCT 519: Coronary access and percutaneous coronary intervention feasibility after transcatheter aortic valve replacement in failed bioprosthetic valves with ACURATE neo2 versus Evolut PRO+

Presenter: Francesco Giannini

October 25, 2023

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

Presentation TCT 2023

TCT 383: Feasibility of TAV-in-TAV in Evolut valves using in-vivo CT sizing and its impact on coronary obstruction and patient prosthesis mismatch

Presenter: Atsushi Okada

October 24, 2023

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Caitlin E. Cox

September 19, 2022

Advertisement

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

AS in Women

Procedural Considerations

Case Background and Valve Selection Discussion

Case Outcome

SMART Data

The Evolution of Transcatheter Mitral Valve Repair: Technical and Procedural Insights from an Early Human Feasibility Program (Case-Based)

TCT 165: Comparison of Paravalvular Leak in SAPIEN 3 and EVOLUT PRO Valves in Transcatheter Aortic Valve Replacement: A Multicenter Registry

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Post-TAVI Conduction Abnormalities: EP Study, Registry Data Provide Snapshots

Durability, Hemodynamics Look Good for SAVR, TAVI in PARTNER 3

VIVA: No Difference Between TAVI and SAVR for Small Aortic Annuli

Optimizing Outcomes With Self-Expanding Valves: The OPTIMIZE PRO Study and Evolut PRO Plus and FX Valves

TCT 248: Assessment of Coronary Cannulation, Commissure and Coronary Alignment post TAVR with the New Supra-Annular, Self-Expanding Evolut FX System

TCT 519: Coronary access and percutaneous coronary intervention feasibility after transcatheter aortic valve replacement in failed bioprosthetic valves with ACURATE neo2 versus Evolut PRO+

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

TCT 383: Feasibility of TAV-in-TAV in Evolut valves using in-vivo CT sizing and its impact on coronary obstruction and patient prosthesis mismatch

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content